Hanna Bandos

Author PubWeight™ 9.14^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	Lancet Oncol	2013	2.59
2	Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.	J Natl Cancer Inst	2013	2.28
3	Regression on quantile residual life.	Biometrics	2009	1.25
4	Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21.	Cancer	2007	0.86
5	Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study.	Cancer Prev Res (Phila)	2013	0.84
6	Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).	Cancer Prev Res (Phila)	2012	0.79
7	Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial.	Neuropsychol Dev Cogn B Aging Neuropsychol Cogn	2012	0.76
8	Exploring Explanatory Models of Risk in Breast Cancer Risk Counseling Discussions: NSABP/NRG Oncology Decision-Making Project 1.	Cancer Nurs	2017	0.75